ZimVie, a life sciences company specializing in dental implants, has entered into a definitive agreement to be acquired by an affiliate of ARCHIMED, an investment firm focused exclusively on healthcare industries.
Under the terms of the merger agreement, ZimVie stockholders will receive $19 in cash for each share of ZimVie common stock outstanding at the closing of the transaction, corresponding to an enterprise value of approximately $730 million. The per share price represents a premium of 99% to the ZimVie 90-day volume-weighted average price (VWAP) of $9.57 per share.
“This transaction marks a new chapter for ZimVie and underscores the value our team has built over the past several years,” said Vafa Jamali, Chairman of the Board and Chief Executive Officer of ZimVie. “Partnering with ARCHIMED will create value for our shareholders while providing the strategic and financial backing to expand our innovative dental technology to more patients globally.”
“We’re excited to partner with ZimVie and its talented team,” said André-Michel Ballester, Managing Partner, at ARCHIMED. “The company has strong fundamentals and compelling growth potential, and we look forward to supporting its next chapter.”
The Board of Directors of ZimVie has unanimously approved the transaction. The transaction is expected to close by year-end 2025, subject to the satisfaction of customary closing conditions, including approval by ZimVie’s stockholders and applicable regulatory approvals.
Upon completion of the transaction, ZimVie will become a privately held company and ZimVie’s shares will no longer be listed on the NASDAQ stock exchange.
